Arvinas Inc (ARVN) Stock Forecast & Price Target

Arvinas is viewed positively because it has effectively removed the commercial overhang around VEPPANU by naming Rigel as the third-party partner, securing $85M upfront plus up to $320M in milestones and tiered royalties while sharing economics 50/50 with Pfizer, and management now believes the company has closed the vepdeg chapter and can redeploy resources into its wholly owned pipeline. With a cash runway into 2H28, the stock trading at cash and near zero enterprise value, and several value-inflecting catalysts expected over the next 12-18 mos, the setup offers strong downside protection and meaningful upside if even one or two programs generate clinically meaningful data. The fundamental optimism is further supported by a sharper portfolio strategy under new CEO Randy Teel, a completed ARV-806 dose escalation with phase 1 data expected this year, and an oral pan-KRAS degrader targeted for filing later this year, all of which create multiple shots at proof-of-concept across oncology and neurology.

Arvinas is viewed negatively because the recent reprioritization appears to signal strategic pressure and uncertainty in the company’s oncology pipeline, with the market likely reading it as a response to competing clinical data rather than purely an internal portfolio optimization. The excerpt suggests RVMD’s Daraxonrasib ASCO ’26 readout may have influenced the decision, implying that a competitor’s ability to address a broad range of RAS-driven tumors across multiple G12 variants could weaken the relative differentiation and commercial appeal of Arvinas’s programs. As a result, the shares may face mild-to-mid weakness as investors reassess the durability of the company’s pipeline value and the risk that its clinical-stage assets, despite multiple candidates such as ARV-102, ARV-806, ARV-393, ARV-027, and vepdegestrant, remain highly dependent on future data and execution.